Literature DB >> 9103451

Glucocorticoids inhibit E-selectin expression by targeting NF-kappaB and not ATF/c-Jun.

C Brostjan1, J Anrather, V Csizmadia, G Natarajan, H Winkler.   

Abstract

E-selectin, an adhesion molecule expressed on the surface of activated endothelial cells, is essential for leukocyte rolling on endothelium which leads to extravasation in the process of inflammation. Induction of E-selectin expression by proinflammatory stimuli such as TNF-alpha or LPS is reduced markedly in the presence of dexamethasone, a synthetic glucocorticoid and potent anti-inflammatory agent. We have investigated the molecular mechanism underlying dexamethasone-mediated E-selectin repression in porcine aortic endothelial cells. Reduced E-selectin protein expression is paralleled by a decrease in E-selectin mRNA and is based on changes in transcription rate. Analysis of the E-selectin promoter revealed that induction by proinflammatory stimuli as well as repression by dexamethasone are mediated by the same promoter region containing three closely spaced binding sites for nuclear factor (NF)-kappaB and an element, NF-ELAM-1 (endothelial leukocyte adhesion molecule-1), constitutively occupied by ATF and c-Jun. NF-ELAM-1 contributes to maximal promoter activity, but does not confer glucocorticoid inhibition, as demonstrated by site-directed mutagenesis. In contrast, transcription directed by the E-selectin NF-kappaB elements is reduced strongly in the presence of dexamethasone, thus identifying NF-kappaB as the primary target for glucocorticoid-mediated E-selectin repression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9103451

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

Review 1.  Molecular mechanisms of glucocorticoid action: what is important?

Authors:  R Newton
Journal:  Thorax       Date:  2000-07       Impact factor: 9.139

Review 2.  Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention.

Authors:  J Panés; M Perry; D N Granger
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

3.  Anti-inflammatory drugs and endothelial cell adhesion molecule expression in murine vascular beds.

Authors:  N Mori; Y Horie; M E Gerritsen; D C Anderson; D N Granger
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

Review 4.  Role of transcription factors in inflammatory lung diseases.

Authors:  I Rahman; W MacNee
Journal:  Thorax       Date:  1998-07       Impact factor: 9.139

5.  Latency-Associated Nuclear Antigen E3 Ubiquitin Ligase Activity Impacts Gammaherpesvirus-Driven Germinal Center B Cell Proliferation.

Authors:  Sofia A Cerqueira; Min Tan; Shijun Li; Franceline Juillard; Colin E McVey; Kenneth M Kaye; J Pedro Simas
Journal:  J Virol       Date:  2016-08-12       Impact factor: 5.103

6.  Induction of the E-selectin promoter by interleukin 1 and tumour necrosis factor alpha, and inhibition by glucocorticoids.

Authors:  K P Ray; S Farrow; M Daly; F Talabot; N Searle
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

7.  Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor.

Authors:  H M Reichardt; J P Tuckermann; M Göttlicher; M Vujic; F Weih; P Angel; P Herrlich; G Schütz
Journal:  EMBO J       Date:  2001-12-17       Impact factor: 11.598

8.  Altered leucocyte trafficking and suppressed tumour necrosis factor alpha release from peripheral blood monocytes after intra-articular glucocorticoid treatment.

Authors:  J H Steer; D T Ma; L Dusci; G Garas; K E Pedersen; D A Joyce
Journal:  Ann Rheum Dis       Date:  1998-12       Impact factor: 19.103

9.  Pan-selectin inhibitors as potential therapeutics for COVID-19 treatment: in silico screening study.

Authors:  Pavel Šmak; Selvaraj Chandrabose; Igor Tvaroška; Jaroslav Koča
Journal:  Glycobiology       Date:  2021-04-01       Impact factor: 4.313

10.  Neutralizing type I IFN antibodies trigger an IFN-like response in endothelial cells.

Authors:  Herwig Peter Moll; Harald Freudenthaler; Anna Zommer; Elisabeth Buchberger; Christine Brostjan
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.